An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.
Also called NCT01340664
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 279 participants
- Registry
-
NCT01340664 -
2010-024256-28
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Mexico, Romania, Russia, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT01340664. Randomized; quadruple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2014-09-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin 50 mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Canagliflozin 150 mg
- Intervention (Drug)
- Metformin
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01340664- Content hash
63e05d4fccd133a03ca5dbe3792350b38aa26c0a3ce4d2554537f2c3cd9ffb1f